Expression of the receptors CD56 and CD16 was assessed on NK cells derived from the peripheral blood (PB, n = 15) and bone marrow (BM, n = 25) aspirates from patients with untreated newly diagnosed AML and compared to PB specimens of healthy donors (HD, n = 12) (for the gating strategy, see Supplementary Materials Figure S1: Gating strategy). Here, FCGR3A is linked to acute myeloid leukemia.